Now more than ever it’s important to choose HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] for 2-dose, 1-month hepatitis B protection.1

Population:

Download PDF

Is the risk close to home?

Traditional 3-dose vaccines may not protect you from hepatitis B.1

HEPLISAV-B gives you faster and higher rates of protection.2,3

Don’t let another day pass without being protected from hepatitis B.

Traditional 3-dose vaccines may not protect you from hepatitis B.1

HEPLISAV-B gives you faster and higher rates of protection.2,3

Don’t let another day pass without being protected from hepatitis B.

Optimal hepatitis B protection is more important than ever

For illustrative purposes only.
map

Select a region

    INDICATION AND IMPORTANT SAFETY INFORMATION
    INDICATION

    HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

    IMPORTANT SAFETY INFORMATION

    Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

    Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

    Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

    The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

    Please see full Prescribing Information.

    Icon of a purple mobile phoneCall 1-84-HEPLISAV (1-844-375-4728) or order online.
    Icon of a purple mobile phone with telephone number to order HEPLISAV-B
    INDICATION AND IMPORTANT SAFETY INFORMATION
    INDICATION

    HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

    IMPORTANT SAFETY INFORMATION

    Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

    Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

    Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

    The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

    Please see full Prescribing Information.

    References:

    1. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 2. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 3. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.